Back
Results - Announcements
Eiko Lifesciences Ltd consolidated sales down 8.67% on year in Q2FY2026, net profit saw a marginal increase of 0.67%
12-Aug-2026, 05:05
Eiko Lifesciences Ltd share price ticked higher by 1.42% to Rs 49.86 after the company's net profit saw a mild growth of 0.67% to Rs 1.51 crore, while revenue from operations eased by 8.67% to Rs 16.75 crore in Q2FY26 over Q1FY26. The market capitalization of Specialty Chemicals industry group stocks on BSE stood at Rs 5.14 lakh crore, expanding by 15.05%. It has marginally improved by 1.63% over last one week and rose by 11.57% in last one month while the market capitalization of Eiko Lifesciences Ltd has softened by 1% and 0.47% in the same period respectively. Profit before tax (PBT) of Eiko Lifesciences Ltd stood at Rs 2.0 crore in Q2 FY26, surging by 36.05% year-on-year, and slipping 0.99% quarter-on-quarter. EBITDA came in at Rs 2 crore, rallying 22.58% YoY and crashing by 29.30% sequentially. Total expenses slightly declined by 7.60% to Rs 15.07 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 13.94 crore, contracting by 16.33% YoY, while employee benefits expense was at Rs 0.2 crore, slipping by 4.76% YoY. For the TTM ended FY26, revenue from operations jumped by 263.86% to Rs 37.66 crore, while net profit plunged by 164.09% to Rs 2.32 crore, compared to previous TTM. EBITDA saw a sharp decline of 531% to Rs 2.04 crore, and PBT tanked by 162.07% to Rs 3.06 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 2.78 crore in FY26, as against Rs 0.33 crore in FY25. Eiko Lifesciences Ltd dropped 7.32% in last one year, significantly underperforming the benchmark BSE Sensex which has eased by 3.04% during the same period.
Eiko Lifesciences Ltd share price ticked higher by 1.42% to Rs 49.86 after the company's net profit saw a mild growth of 0.67% to Rs 1.51 crore, while revenue from operations eased by 8.67% to Rs 16.75 crore in Q2FY26 over Q1FY26. The market capitalization of Specialty Chemicals industry group stocks on BSE stood at Rs 5.14 lakh crore, expanding by 15.05%. It has marginally improved by 1.63% over last one week and rose by 11.57% in last one month while the market capitalization of Eiko Lifesciences Ltd has softened by 1% and 0.47% in the same period respectively. Profit before tax (PBT) of Eiko Lifesciences Ltd stood at Rs 2.0 crore in Q2 FY26, surging by 36.05% year-on-year, and slipping 0.99% quarter-on-quarter. EBITDA came in at Rs 2 crore, rallying 22.58% YoY and crashing by 29.30% sequentially. Total expenses slightly declined by 7.60% to Rs 15.07 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 13.94 crore, contracting by 16.33% YoY, while employee benefits expense was at Rs 0.2 crore, slipping by 4.76% YoY. For the TTM ended FY26, revenue from operations jumped by 263.86% to Rs 37.66 crore, while net profit plunged by 164.09% to Rs 2.32 crore, compared to previous TTM. EBITDA saw a sharp decline of 531% to Rs 2.04 crore, and PBT tanked by 162.07% to Rs 3.06 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 2.78 crore in FY26, as against Rs 0.33 crore in FY25. Eiko Lifesciences Ltd dropped 7.32% in last one year, significantly underperforming the benchmark BSE Sensex which has eased by 3.04% during the same period.